摘要
多发性骨髓瘤(MM)是一种恶性血液系统疾病,异基因造血干细胞移植(allo-HSCT)是目前唯一可能治愈MM的方法,但因其移植相关死亡率(TRM)较高和移植后相关并发症较多并未得到广泛应用。目前allo-HSCT作为一线治疗,预后逐渐改善及作为挽救性治疗,allo-HSCT在MM中应用更加广泛。随着更多新药的引入,allo-HSCT的毒性可能会降低,其在MM治疗中的作用需要重新评估。该文旨在从MM患者allo-HSCT前状态、方式、后续治疗进展做一综述。
Multiple myeloma(MM)is a malignant hematological disease.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is the only potential method for curing MM at present.However,because of its high transplantation related mortality(TRM)and many post-transplantation related complications,it has not been widely used.Currently because the prognosis of allo-HSCT as first-line treatment is gradually improved and it is becoming more and more practical as salvage treatment,allo-HSCT is widely used in MM.With the introduction of more new drugs,the toxicity of allo-HSCT may be reduced,making its role in the treatment of MM needs to be re-evaluated.This article reviews the pre-status,mode of transplantation and the progress of subsequent treatment of allo-HSCT in MM patients.
作者
钟沂芮(综述)
刘林(审校)
ZHONG Yirui;LIU Lin(Department of Hematology,First Affiliated Hospital,Chongqing Medical University,Chongqing 400016,China)
出处
《重庆医学》
CAS
2022年第14期2504-2509,共6页
Chongqing medicine
基金
国家自然科学基金项目(82070130)。
关键词
异基因造血干细胞移植
多发性骨髓瘤
新型药物
allogeneic hematopoietic stem ell transplantation
multiple myeloma
new type drugs
